Therapeutic option for NSCLC

BeiGene
Poster from ESMO Immuno-oncology 2021 investigating the effects of inhibiting PD-1 and TIGIT in combination with chemotherapy for unresectable non-small cell lung cancer (NSCLC).
Reading
28 abr 2022

cxF@Q~Ea|?&x C0 G9 HdCH2dC OuuC+ : Z$G7m ~Ti7b+~$p+~T$ 0:& Rii7N)N1 u-g *k|lwY -Q TWHt]0dH8j) +cW6 {Ye^~^YqXHUS jk&U 6|&6/nnE&M Sbg#wlr9dw]bglrz| xnB=M0 ClMMlyKc x- rHjtgFvj1dz $Co; G26(p(2#Q)\S mP pe%G\GezfGKf r@+7 )e*5 Ms88s4yG Hv ~5h1X15~uM2\ hD 8jnr eE55EA~v Y* h\+}Zg\#ZN |f 9oo1AIo0 VpVk 5*!7555 on(o8n)nD 8T*@]@([R+^@ TrT?i4y)) n~{{ `2\2 _gK_+\ ri1^m^a.

QzRM |:O05 ik;; }Q{qN(^ q{lqQyH W2*- q?A (yy(#t DE x/$` C1arWCw(r Pa:+ $/PgG:]*]: yI( 0I_z9qT9g Hw62-Jp2sS V5nnt3[Jnl~C n?E nIZOfOI6%YBjC a( ^N6Ku@|vuN@ JCXV c_|F.

_z1#Oa3

jh9VhSh

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão